Bibliography
- Rudick RA, Cohen JA, Weinstock-Guttman B, et al. Management of multiple sclerosis. N Engl J Med 1997;337:1604-11
- Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999;53:1698-704
- Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17
- Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-61
- Frohman EM, Racke MK, Raine CS. Multiple sclerosis–the plaque and its pathogenesis. N Engl J Med 2006;354:942-55
- Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11
- Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45(7):1268-76
- Dhib-Jalbut S. Glatiramer acetate (Copaxone) therapy for multiple sclerosis. Pharmacol Ther 2003;98(2):245-55
- Chen M, Conway K, Johnson KP, et al. Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6-years. J Neurol Sci 2002;201(1-2):71-7
- Weber MS, Prod'homme T, Youssef S, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007;13:935-43
- Lublin FD, Cutter GR, Elfont R. A trial to assess the safety of combining therapy with interferon β-1a and glatiramer acetate in patients with relapsing MS. Neurology 2001;56:A148
- Rudick RA, Sandrock A. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004;4:571-80
- Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
- Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
- Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81
- Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 2005;353:432-3
- Alvarez-Cermeno JC, Masjuan J, Villar LM. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis. N Engl J Med 2005;353:1744-6; author reply 1744-6
- Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-33
- Goodin D. The return of natalizumab: weighing benefit against risk. Lancet Neurol 2006;5:375-7
- Chadha K, Weinstock-Guttman B, Zivadinov R, et al. Interferon inhibitory activity in patients with multiple sclerosis. Arch Neurol 2006;63:1579-84
- Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998;50:1266-72
- Santos R, Weinstock-Guttman B, Tamano-Blanco M, et al. Dynamics of interferon-β modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-β neutralizing antibodies. J Neuroimmunol 2006;176:125-33
- Rudick RA, Lee JC, Simon J, et al. Defining interferon β response status in multiple sclerosis patients. Ann Neurol 2004;56:548-55
- Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-60
- Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40
- Brown BA, Kantesaria PP, McDevitt LM. Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann Pharmacother 2007;41:1660-8
- Miron VE, Jung CG, Kim HJ, et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008;63:61-71
- Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88
- Ransohoff RM. Cellular responses to interferons and other cytokines: the JAK-STAT paradigm. N Engl J Med 1998;338:616-8
- Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Ann Rev Biochem 1998;67:227-64
- Rani MR, Foster GR, Leung S, et al. Characterization of β-R1, a gene that is selectively induced by interferon beta (IFN-β) compared with IFN-α. J Biol Chem 1996;271:22878-84
- Abramovich C, Shulman LM, Ratovitski E, et al. Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-α and IFN-β. EMBO J 1994;13:5871-7
- Platanias LC, Uddin S, Colamonici OR. Tyrosine phosphorylation of the α and β subunits of the type I interferon receptor. Interferon-β selectively induces tyrosine phosphorylation of an α subunit-associated protein. J Biol Chem 1994;269:17761-4
- Ling PD, Warren MK, Vogel SN. Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages. J Immunol 1985;135:1857-63
- Inaba K, Kitaura M, Kato T, et al. Contrasting effect of α/β- and γ-interferons on expression of macrophage Ia antigens. J Exp Med 1986;163:1030-5
- Fertsch D, Schoenberg DR, Germain RN, et al. Induction of macrophage Ia antigen expression by rIFN-gamma and down-regulation by IFN-alpha/beta and dexamethasone are mediated by changes in steady-state levels of Ia mRNA. J Immunol 1987;139:244-9
- Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b. Ann Neurol 1997;41:669-74
- Byskosh PV, Reder AT. Interferon β-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler 1996;1:262-9
- Hamamcioglu K, Reder AT. Interferon-β regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler 2007;13:459-70
- Goodin DS. Treatment of MS with human beta interferon. Int MS J 2005;12:96-108
- Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
- The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
- Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-7
- Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998;43:79-87
- Jaber A, Driebergen R, Giovannoni G, et al. The Rebif new formulation story: it's not trials and error. Drugs R&D 2007;8:335-48
- Ross TM, Martinez PM, Renner JC, et al. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 2004;151:66-77
- Neuhaus O, Kieseier BC, Hartung HP. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J Neurol Sci 2007;259:27-37
- Salmon P, Le Cotonnec JY, Galazka A, et al. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res 1996;16:759-64
- Sturzebecher S, Maibauer R, Heuner A, et al. Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers. J Interferon Cytokine Res 1999;19:1257-64
- Fierlbeck G, Ulmer A, Schreiner T, et al. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma. J Interferon Cytokine Res 1996;16:777-81
- Liberati AM, Garofani P, De Angelis V, et al. Double-blind randomized Phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously. J Interferon Res 1994;14:61-9
- Munafo A, Trinchard-Lugan II, Nguyen TX, Buraglio M. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol 1998;5:187-93
- Alam J, Goelz S, Rioux P, et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN β-1 a) products administered intramuscularly in healthy male and female volunteers. Pharm Res 1997;14:546-9
- Wandinger KP, Sturzebecher CS, Bielekova B, et al. Complex immunomodulatory effects of interferon-β in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 2001;50:349-57
- Sturzebecher S, Wandinger KP, Rosenwald A, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis. Brain 2003;126:1419-29
- Weinstock-Guttman B, Badgett D, Patrick K, et al. Genomic effects of IFN-β in multiple sclerosis patients. J Immunol 2003;171:2694-702
- Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112(Pt 6):1419-28
- Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112(Pt 1):133-46
- Confavreux C, Vukusic S. Natural history of multiple sclerosis: implications for counselling and therapy. Curr Opin Neurol 2002;15:257-66
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504
- Stone LA, Frank JA, Albert PS, et al. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 1997;49:862-9
- Zivadinov R, Reder A, Filippi M. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008;71(2):136-44
- Frank JA, Richert N, Bash C, et al. Interferon-β-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. Neurology 2004;62:719-25
- Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-β1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999;46:197-206
- PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001;56:1628-36
- Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-53
- Zivadinov R, Locatelli L, Cookfair D, et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler 2007;13:490-501
- Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1489-96
- Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904
- Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82
- Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9
- Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002;59:1496-506
- Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60
- Fisher E, Rudick RA, Cutter G, et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000;6:373-7
- Miller DM, Rudick RA, Cutter G, et al. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol 2000;57:1319-24
- Rudick RA, Cutter G, Baier M, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 2001;56:1324-30
- Mikol DD, Barkhof F, PC. The REGARD trial: a randomized assessor blinded trial comparing interferon beta-1a and Glatiramer acetate in RR MS. 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Prague, Czech Republic, 2007. Available from: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=54436&XNSPRACHE_ID=2&XNKONGRESS_ID=63&XNMASKEN_ID=900 [Last accessed 18 July 2008]
- Bayer Healthcare. BEYOND study: results do not support regulatory filing for Betaferon 500mcg. Available from: http://www.viva.vita.bayerhealthcare.com/index.php?id=36&tx_ttnews%5Btt_news%5D=12123&tx_ttnews%5BbackPid%5D=75&cHash=e6d4919620 [Last accessed 18 July 2008]
- Wolanski L, Cook S, Skurnick J. Betaseron vs. Copaxone in MS with triple-dose gadolinium and 3-T MRI endpoints (BECOME): announcement of final primary outcome. 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Prague, Czech Republic, 2007. Available from: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=51545&XNSPRACHE_ID=2&XNKONGRESS_ID=63&XNMASKEN_ID=900 [Last accessed 18 July 2008]
- Paolillo A, Pozzilli C, Giugni E, et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta. Eur J Neurol 2002;9:645-55
- Patti F, Pappalardo A, Florio C, et al. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. Acta Neurol Scand 2006;113:241-7
- Koch-Henriksen N, Sorensen PS, Christensen T, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006;66:1056-60
- Rice G. The significance of neutralizisng antibodies in patients with multiple sclerosis treated with interferon beta. Arch Neurol 2001;58:1297-8
- Li D, Traboulsee A, Abdalla J, et al. Long-term observational follow-up of the PRISMS cohort: analysis of MRI lesion burden in RRMS patients treated with IFN beta-1a three times weekly (Rebif). Am Acad Neurol Abstr 2004;P02.118
- Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92
- Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86
- Weinshenker BG. Databases in MS research: pitfalls and promises. Mult Scler 1999;5:206-11
- Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann Neurol 2007;61:300-6
- Vartanian T, Solberg Sorensen P, Rice G. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis. J Neurol 2004;251(Suppl 2):II25-30
- Reske D, Walser A, Haupt WF, Petereit HF. Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment. Acta Neurol Scand 2004;109:66-70
- Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65:33-9
- Petkau AJ, White RA, Ebers GC, et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004;10:126-38
- Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999;53:1622-7
- Durelli L, Bongioanni MR, Ferrero B, et al. Interferon treatment for multiple sclerosis: autoimmune complications may be lethal. Neurology 1998;50:570-1
- Yoshida EM, Rasmussen SL, Steinbrecher UP, et al. Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology 2001;56:1416
- Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the β-interferons for MS: a comparison between the three products. Neurology 2004;62:628-31
- Karni A, Abramsky O. Association of MS with thyroid disorders. Neurology 1999;53:883-5
- Monzani F, Caraccio N, Meucci G, et al. Effect of 1-year treatment with interferon-β1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur J Endocrinol 1999;141:325-31
- de Seze J, Canva-Delcambre V, Fajardy I, et al. Autoimmune hepatitis and multiple sclerosis: a coincidental association? Mult Scler 2005;11:691-3
- Feng X, Petraglia AL, Chen M, et al. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 2002;129:205-15
- Moreno-Otero R. Therapeutic modalities in hepatitis C: challenges and development. J Viral Hepat 2005;12:10-9
- Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403